Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept treat-and-extend versus standard care for neovascular age-related macular degeneration
2015-002302-36Phase 2Unknown
- Sponsor
- York and Scarborough Teaching Hospitals NHS Foundation Trust
- Start
- Jul 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of aflibercept in exudative macular degeneration (2 arms), sponsored by York and Scarborough Teaching Hospitals NHS Foundation Trust. Primary endpoint: Feasibility of conducting the randomized controlled trial. Status: unknown.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2015-002302-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002302-36.